96 related articles for article (PubMed ID: 10894297)
1. Elicitation of protective immunity against simian immunodeficiency virus infection by a recombinant Sendai virus expressing the Gag protein.
Kano M; Matano T; Nakamura H; Takeda A; Kato A; Ariyoshi K; Mori K; Sata T; Nagai Y
AIDS; 2000 Jun; 14(9):1281-2. PubMed ID: 10894297
[No Abstract] [Full Text] [Related]
2. Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.
Zhao J; Pinczewski J; Gómez-Román VR; Venzon D; Kalyanaraman VS; Markham PD; Aldrich K; Moake M; Montefiori DC; Lou Y; Pavlakis GN; Robert-Guroff M
J Virol; 2003 Aug; 77(15):8354-65. PubMed ID: 12857905
[TBL] [Abstract][Full Text] [Related]
3. Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys.
Someya K; Xin KQ; Ami Y; Izumi Y; Mizuguchi H; Ohta S; Yamamoto N; Honda M; Okuda K
Virology; 2007 Oct; 367(2):390-7. PubMed ID: 17628628
[TBL] [Abstract][Full Text] [Related]
4. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection.
Egan MA; Charini WA; Kuroda MJ; Schmitz JE; Racz P; Tenner-Racz K; Manson K; Wyand M; Lifton MA; Nickerson CE; Fu T; Shiver JW; Letvin NL
J Virol; 2000 Aug; 74(16):7485-95. PubMed ID: 10906202
[TBL] [Abstract][Full Text] [Related]
5. Central nervous system-specific consequences of simian immunodeficiency virus Gag escape from major histocompatibility complex class I-mediated control.
Beck SE; Queen SE; Viscidi R; Johnson D; Kent SJ; Adams RJ; Tarwater PM; Mankowski JL
J Neurovirol; 2016 Aug; 22(4):498-507. PubMed ID: 26727909
[TBL] [Abstract][Full Text] [Related]
6. Intravenous inoculation of replication-deficient recombinant vaccinia virus DIs expressing simian immunodeficiency virus gag controls highly pathogenic simian-human immunodeficiency virus in monkeys.
Izumi Y; Ami Y; Matsuo K; Someya K; Sata T; Yamamoto N; Honda M
J Virol; 2003 Dec; 77(24):13248-56. PubMed ID: 14645581
[TBL] [Abstract][Full Text] [Related]
7. CD4+ T cell responses to simian immunodeficiency virus.
Mills KH; Jones WC
Curr Top Microbiol Immunol; 1994; 188():161-73. PubMed ID: 7924425
[No Abstract] [Full Text] [Related]
8. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and protective efficacy of Gag/Pol/Env vaccines derived from temporal isolates of SIVmne against cognate virus challenge.
Polacino P; Cleveland B; Zhu Y; Kimata JT; Overbaugh J; Anderson D; Hu SL
J Med Primatol; 2007 Aug; 36(4-5):254-65. PubMed ID: 17669214
[TBL] [Abstract][Full Text] [Related]
10. Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors.
Nakaya Y; Nakaya T; Park MS; Cros J; Imanishi J; Palese P; García-Sastre A
J Virol; 2004 Sep; 78(17):9366-75. PubMed ID: 15308731
[TBL] [Abstract][Full Text] [Related]
11. T-cell vaccination reduces simian immunodeficiency virus levels in semen.
Whitney JB; Luedemann C; Hraber P; Rao SS; Mascola JR; Nabel GJ; Letvin NL
J Virol; 2009 Oct; 83(20):10840-3. PubMed ID: 19640980
[TBL] [Abstract][Full Text] [Related]
12. Broadening of CD8+ cell responses in vaccine-based simian immunodeficiency virus controllers.
Iwamoto N; Tsukamoto T; Kawada M; Takeda A; Yamamoto H; Takeuchi H; Matano T
AIDS; 2010 Nov; 24(18):2777-87. PubMed ID: 21045637
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of early versus late viral proteins in vaccination against SIV.
Stittelaar KJ; Gruters RA; Schutten M; van Baalen CA; van Amerongen G; Cranage M; Liljeström P; Sutter G; Osterhaus AD
Vaccine; 2002 Jul; 20(23-24):2921-7. PubMed ID: 12126903
[TBL] [Abstract][Full Text] [Related]
14. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
[TBL] [Abstract][Full Text] [Related]
15. Improved protection against simian immunodeficiency virus mucosal challenge in macaques primed with a DNA vaccine and boosted with the recombinant modified vaccinia virus Ankara and recombinant Semliki Forest virus.
Martinon F; Brochard P; Ripaux M; Delache B; Aurégan G; Vaslin B; Le Grand R
Vaccine; 2008 Jan; 26(4):532-45. PubMed ID: 18093703
[TBL] [Abstract][Full Text] [Related]
16. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.
McKenna PM; Koser ML; Carlson KR; Montefiori DC; Letvin NL; Papaneri AB; Pomerantz RJ; Dietzschold B; Silvera P; McGettigan JP; Schnell MJ
J Infect Dis; 2007 Apr; 195(7):980-8. PubMed ID: 17330788
[TBL] [Abstract][Full Text] [Related]
17. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques.
Malkevitch N; Patterson LJ; Aldrich K; Richardson E; Alvord WG; Robert-Guroff M
J Immunol; 2003 Apr; 170(8):4281-9. PubMed ID: 12682263
[TBL] [Abstract][Full Text] [Related]
18. Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques.
Stevceva L; Alvarez X; Lackner AA; Tryniszewska E; Kelsall B; Nacsa J; Tartaglia J; Strober W; Franchini G
J Virol; 2002 Nov; 76(22):11659-76. PubMed ID: 12388726
[TBL] [Abstract][Full Text] [Related]
19. T-cell-mediated protective efficacy of a systemic vaccine approach in cynomolgus monkeys after SIV mucosal challenge.
Michelini Z; Negri DR; Baroncelli S; Catone S; Comini A; Maggiorella MT; Sernicola L; Crostarosa F; Belli R; Mancini MG; Farcomeni S; Fagrouch Z; Ciccozzi M; Rovetto C; Liljestrom P; Norley S; Heeney J; Titti F
J Med Primatol; 2004 Oct; 33(5-6):251-61. PubMed ID: 15525326
[TBL] [Abstract][Full Text] [Related]
20. Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity.
Ami Y; Izumi Y; Matsuo K; Someya K; Kanekiyo M; Horibata S; Yoshino N; Sakai K; Shinohara K; Matsumoto S; Yamada T; Yamazaki S; Yamamoto N; Honda M
J Virol; 2005 Oct; 79(20):12871-9. PubMed ID: 16188989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
